Compare DVN & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVN | EW |
|---|---|---|
| Founded | 1971 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1B | 49.9B |
| IPO Year | 1999 | 1999 |
| Metric | DVN | EW |
|---|---|---|
| Price | $42.19 | $90.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 21 |
| Target Price | $50.15 | ★ $96.37 |
| AVG Volume (30 Days) | ★ 14.2M | 4.6M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.19 | ★ 0.66 |
| Revenue | ★ $17,188,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $28.91 | $13.39 |
| Revenue Next Year | $8.55 | $9.81 |
| P/E Ratio | $223.87 | ★ $135.95 |
| Revenue Growth | 7.83 | ★ 11.55 |
| 52 Week Low | $31.45 | $72.30 |
| 52 Week High | $52.71 | $91.65 |
| Indicator | DVN | EW |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 63.09 |
| Support Level | $41.73 | $82.02 |
| Resistance Level | $46.70 | N/A |
| Average True Range (ATR) | 1.34 | 2.28 |
| MACD | -0.12 | 0.23 |
| Stochastic Oscillator | 9.25 | 78.69 |
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two-thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. After the merger with Coterra, it will have a foothold in the gas-driven Appalachian Basin as well. At the end of 2025, Devon reported net proved reserves of 2.4 billion barrels of oil equivalent, up from 2.2 billion in 2024. Net production averaged roughly 840,000 barrels of oil equivalent per day in 2025 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.